Pfizer stock may not be as hyped as the COVID-19 business looks to wind down. However, with a renewed growth strategy, PFE stock can offer investors growth at a value price.
Shares of COVID vaccine maker Pfizer (PFE) are steadily trending higher again.The $300 billion biopharmaceutical company doesn’t get nearly as much press as it did a few years ago. Undoubtedly, Pfizer was met with much praise following the miraculous marvel that’s since been taken for granted.
Even as the COVID-19 business winds down, Pfizer remains one of this market’s most innovative companies and the 12.3 times trailing earnings multiple does not do its justice.
With a new growth mindset and investment in other intriguing businesses, Pfizer stock seems eager to prove it’s worthy of a much higher multiple. With a stellar management team and discounted growth capabilities, stock attempts to revisit its highs near $60 per share.
Access 10,000+ financial instruments Auto open & close positions News & economic calendar Technical indicators & charts Many more tools included
By supplying your email you agree to FP Markets privacy policy and receive future marketing materials from FP Markets. You can unsubscribe at any time.
Source - cache | Page ID - 825
